Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cylene Pharmaceuticals has started a multi-center Phase I clinical trial of their oral CK2 inhibitor CX-4945 in patients with multiple myeloma.
Subscribe to our email newsletter
The primary objectives of the study are to determine the safety, tolerance and pharmacokinetic (PK) properties of CX-4945 in multiple myeloma patients and to select the appropriate dose for Phase II trials.
However, the secondary objectives are to investigate the pharmacodynamic (PD) activity of CX-4945 using mechanism and tumor-related PD biomarkers that have been validated in both preclinical and clinical studies.
In preclinical studies with multiple myeloma cell lines, CX-4945 inhibited critical CK2-mediated events including key signaling pathways and mediators (PI3K/Akt, NFkB, IL-6) that are known to drive the proliferation of multiple myeloma.
Cylene Pharma president and CEO said that clinical advancement of CK2 inhibitor, CX-4945, in patients with multiple myeloma represents another major milestone for Cylene.